- Report
- November 2026
- 376 Pages
Global
From €5466EUR$5,850USD£4,566GBP
- Report
- January 2026
- 180 Pages
Global
From €4205EUR$4,500USD£3,513GBP
- Report
- March 2026
- 149 Pages
Global
From €3737EUR$3,999USD£3,122GBP
- Report
- December 2025
- 150 Pages
Global
From €4532EUR$4,850USD£3,786GBP
- Report
- August 2026
- 160 Pages
Global
From €3102EUR$3,320USD£2,592GBP
€3878EUR$4,150USD£3,239GBP
- Report
- August 2026
- 160 Pages
Global
From €3102EUR$3,320USD£2,592GBP
€3878EUR$4,150USD£3,239GBP
- Report
- September 2026
- 191 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- September 2026
- 180 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- February 2026
- 144 Pages
Global
From €3691EUR$3,950USD£3,083GBP
- Report
- August 2026
- 160 Pages
Global
From €3102EUR$3,320USD£2,592GBP
€3878EUR$4,150USD£3,239GBP
- Report
- June 2026
- 200 Pages
Global
From €2794EUR$2,990USD£2,334GBP
- Report
- April 2026
- 200 Pages
Global
From €2794EUR$2,990USD£2,334GBP
- Report
- September 2026
- 191 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- September 2026
- 185 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- September 2026
- 184 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- September 2026
- 194 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- January 2026
- 184 Pages
Global
From €3313EUR$3,545USD£2,767GBP
€3681EUR$3,939USD£3,075GBP
- Report
- November 2026
- 189 Pages
Global
From €5466EUR$5,850USD£4,566GBP
- Report
- February 2026
- 250 Pages
Global
From €4195EUR$4,490USD£3,505GBP
- Report
- February 2026
- 250 Pages
Global
From €4195EUR$4,490USD£3,505GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more